Salutem Insights Ltd.’s Post

Kudos to AI in Precision Oncology editor Blythe Adamson, PhD, MPH, for her thoughtful and careful application of real-world evidence (RWE) to complement clinical trials. RWE plays a crucial role in addressing questions that traditional trials may not fully answer, particularly when utilizing large and diverse datasets. Blythe’s work underscores the importance of RWE in enhancing our understanding of treatment outcomes and patient care. Keep pushing forward, Blythe—excited to see the innovative solutions you bring to cancer research (and your manuscripts :)) Flatiron Health James Hamrick #CancerResearch #RealWorldEvidence #ClinicalTrials #OncologyInnovation

Raising awareness of this excellent Australian Symposium on Precision Oncology. Registrations open. #APOS2024 #APOS24 #CancerMeetsItsMatch #CancerResearch #Omico #CancerTreatment #ZoomWebinar #CancerCare #GroundbreakingResearch #InnovativeMedicine #HealthcareTech #VirtualLearning #FightCancer #ResearchforCure #Research #CancerAwareness #BeatCancer #MedicalInnovations #CancerSolutions #MedicalBreakthroughs #OncologyResearch #ScienceAndHealth #CancerInsights #LifeScience

The demand for #RWD on patients with cancer in Europe and Japan is increasing, particularly as many regulatory and #HTA bodies have stated a clear preference for local data in guidance on #RWE. At Flatiron Health, we're addressing this gap by now having EHR-derived data from the UK, Germany, and Japan. Hear Blythe Adamson, PhD, MPH, Head of Outcomes Research & Evidence Generation, share how Flatiron is filling critical evidence generation gaps with global oncology #realworlddata.

Last year's Advanced Research Projects Agency for Health (ARPA-H) Dash to Accelerate Health Outcomes challenged researchers and health advocates to submit their ideas to transform U.S. health within the next 20 years. The winner of that competition, Prosetta Biosciences Inc, is pushing for results much earlier than that. Their winning entry was titled, One Drug for All Cancers. Since the ARPA-H Dash, they have worked with the National Cancer Institute (NCI) to test their cancer therapeutic, PAV-541 and report groundbreaking results. They are now looking to move into FDA Phase I clinical trials in less than 12 months. Read their results and learn more about their journey below. #Bioscience #CancerResearch #Funding #Results #Therapeutic #PAV541 #STEM #Health #HealthOutcomes

The diagnosis of #cancer has repercussions not only for patients, but also for those around them. That's why we urgently need to rekindle hope in the hearts of all those affected. Servier has chosen to highlight recent developments in therapeutic innovation through its first edition of the Therapeutics Innovation Summit (#THRPTX) that will take place on June 18, 2024, at our R&D Institute in #ParisSaclay. This summit, under the valuable patronage of Professor William G. Kaelin Jr., a Harvard University professor of Medicine and recipient of the 2019 #NobelPrize in Medicine, will bring together nearly 200 eminent international experts, decision-makers, researchers, renowned scientists, and medical professionals. It will be the perfect opportunity to illustrate just how essential transactional and collaborative medicine is for driving innovation at the service of the patient in the best and most sustainable way. In a world where, according to 2022 World Health Organization figures, cancer is the second leading cause of death, we believe it is absolutely vital to work towards accelerating access to treatment, and thus improving the overall patient care experience. Stay tuned to follow future developments that bring new hope for patients and their loved ones! #WeAreServier #MovedByYou #Health #oncology

Delighted to share a compelling new report outlining the policy actions needed to prepare health systems for the future of #advanceddiagnostics, in order to transform outcomes for people with #cancer.    Published by The Health Policy Partnership and supported by AstraZeneca as well as other industry partners, the report was developed alongside an expert steering committee with the aim of future-proofing the oncology diagnostics ecosystem.     The report considers the future of diagnostics, including how they could benefit patients, and sets out five priority areas where policymakers should take action to support their widespread adoption. Please do take a look and share within your networks. https://lnkd.in/e9BDGsM7    Thanks to all those involved in bringing this important policy report to life for your support and partnership!    #PrecisionMedicine #HealthcareInnovation  GE HealthCare, Vijay Andani, SOPHiA GENETICS,  Ibex Medical Analytics, Kimberly Gasuad   Greg Rossi, Kristina Rodnikova, Sara Correia Marques, Grace Hughes, France Dube, Elisa Agate 

Our 2024 annual report has been released! 📖 Deep dive into a year marked by numerous achievements, such as meaningful new partnerships in R&D, breakthrough innovations in oncology and skin care, and relentless commitments to support health care professionals and our local communities. Among other topics, discover our renewed dermo-cosmetic strategy as well as how our research teams are making significant strides in targeted oncology. As put in his foreword by Eric Ducournau, CEO of Pierre Fabre Laboratories: «Innovating means fighting cancer and rare diseases, developing best-in- class dermo-cosmetic care products, co-innovating with our partners. These are the “new ways to care” championed by Pierre Fabre Laboratories, which we are proud to share with you in this annual report. » Read it now online 👉 https://lnkd.in/dT8VkpD3 #PierreFabre #NewWaysToCare #AnnualReport #Innovation #Science

🔝 Thanks to our expertise in regulatory affairs, at ASPHALION we are in charge of the Regulatory part of this #EUfunded project, focused on the submission of the #clinicaltrial and the #safety management plan. ▶ PragmaTIL aims to optimize treatment of #cancer patients with Tumour-Infiltrating Lymphocytes Adoptive #CellTherapy (TIL-ACT) and substantially expand and improve the #clinical implementation of this treatment modality in academic hospitals.    📧 For further information, you can contact us at: horizon@asphalion.com     ➕ To learn more about #PragmaTIL, please visit: www.pragmatil.eu    #CTIS #ClinicalTrials #Safety #TILs #RA #HORIZON #EU #RegulatoryAffairs #EquitableAccess #Patientcentered #DisruptiveInnovativeTherapy #WeAreAsphalion#WeCare #KnowledgeFromExperience    

Thanks to the 21st Century Cures Act and healthcare technology advances, #RWD is recognized as vital for understanding diseases and improving patient care. Understanding the quality of #RWD is essential to generating confidence in the #RWE resulting from its use. Multiple dimensions of quality must be assessed when making a fit-for-use determination—this new study, published in American Society of Clinical Oncology (ASCO)'s JCO Clinical Cancer Informatics, summarizes guidance around data quality from key regulatory and policy bodies, providing a framework for evaluating quality across multiple dimensions. Researchers aim to create transparency in how data quality can be assessed in scaled, EHR-based datasets. Visit our website to learn more and for a link to the full publication: https://lnkd.in/eEcQhc2S

Great podcast listen here about the importance of representation in oncology clinical trials, the role of technology in clinical trials, creating more access to clinical trials, and improving clinical trial design.